NexGenix awarded Phase I grant from NINDS for development of novel small molecule Hsp90 therapeutics

NexGenix Pharmaceuticals Holdings, Inc. a privately-held biotechnology company with a portfolio of novel targeted therapies for oncology and neurodegenerative disorders, based in New York City, today announced that it has been awarded a Phase I grant from the NIH, National Institute of Neurological Disorders and Stroke (NINDS) for the Development Of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma. Hsp90 is also a drug target for the treatment of ALS. The grant of up to $118,000 was awarded under the Small Business Innovation Research Program (SBIR) Initiative. The SBIR program is a set-aside program for domestic small business concerns to engage in Research/Research and Development (R&D) that has the potential for commercialization.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail